Search

Your search keyword '"Leblanc, Richard"' showing total 1,034 results
Start Over Author "Leblanc, Richard"
1,034 results on '"Leblanc, Richard"'

2. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Author

Baljevic, Muhamed, Gasparetto, Cristina, Schiller, Gary, Tuchman, Sascha, Callander, Natalie, Lentzsch, Suzanne, Monge, Jorge, Kotb, Rami, Bahlis, Nizar, White, Darrell, Chen, Christine, Sutherland, Heather, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher, Bensinger, William, Biran, Noa, DeCastro, Andrew, Van Domelen, Dane, Zhang, Chris, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Bentur, Ohad, and Lipe, Brea

Subjects
anti‐BCMA, multiple myeloma, selinexor
Abstract

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.

Published
2022

3. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Author

Venner, Christopher P., Duggan, Peter, Song, Kevin, Reece, Donna, Sharma, Smriti, Su, Jiandong, Jimenez-Zepeda, Victor H., McCurdy, Arleigh, Louzada, Martha, Mian, Hira, Sebag, Michael, White, Darrell, Stakiw, Julie, Kotb, Rami, Aslam, Muhammad, Reiman, Anthony, Gul, Engin, Chu, Michael P., Bergstrom, Debra, and LeBlanc, Richard

Published
2024
Full Text
View/download PDF

4. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, Schiller, Gary J, Tuchman, Sascha A, Callander, Natalie S, Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C, Kotb, Rami, White, Darrell, Bahlis, Nizar J, Chen, Christine I, Sutherland, Heather J, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P, Bensinger, William I, Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Cancer, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Administration Schedule, Female, Humans, Hydrazines, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma, Oligopeptides, Survival Analysis, Translocation, Genetic, Treatment Outcome, Triazoles, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).MethodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m2) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.ResultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m2, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.ConclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Published
2022

5. Slope Stability, Performance and Berm Design of Small Arms Ranges for the Canadian Armed Forces

Author

LeBlanc, Richard, Skordaki, Maria, Vlachopoulos, Nicholas, Zheng, Zheng, Editor-in-Chief, Xi, Zhiyu, Associate Editor, Gong, Siqian, Series Editor, Hong, Wei-Chiang, Series Editor, Mellal, Mohamed Arezki, Series Editor, Narayanan, Ramadas, Series Editor, Nguyen, Quang Ngoc, Series Editor, Ong, Hwai Chyuan, Series Editor, Sun, Zaicheng, Series Editor, Ullah, Sharif, Series Editor, Wu, Junwei, Series Editor, Zhang, Baochang, Series Editor, Zhang, Wei, Series Editor, Zhu, Quanxin, Series Editor, Zheng, Wei, Series Editor, Javankhoshdel, Sina, editor, and Abolfazlzadeh, Yousef, editor

Published
2023
Full Text
View/download PDF

6. A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients

Author

Roy, Jean, Cohen, Sandra, Sauvageau, Guy, Ahmad, Imran, Fournier, Valentyn, Terra, Rafik, Caudrelier, Pierre, Thiant, Stéphanie, Thauvette, Gabrielle, Bambace, Nadia, Delisle, Jean-Sébastien, Lachance, Silvy, Kiss, Thomas, Bernard, Léa, Roy, Denis Claude, Veilleux, Olivier, and LeBlanc, Richard

Published
2024
Full Text
View/download PDF

8. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Author

Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, and Reece, Donna

Published
2023
Full Text
View/download PDF

13. Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database

Author

Mian, Hira, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Kardjadj, Moustafa, Jimenez-Zepeda, Victor H, Song, Kevin, Louzada, Martha, LeBlanc, Richard, Sebag, Michael, White, Darrell, Stakiw, Julie, Reiman, Anthony, Kotb, Rami, Aslam, Muhammad, Gul, Engin, and Venner, Christopher P.

Published
2022
Full Text
View/download PDF

14. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

15. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Author

LeBlanc, Richard, Thiant, Stéphanie, Terra, Rafik, Ahmad, Imran, Claveau, Jean-Sébastien, Bambace, Nadia, Bernard, Léa, Cohen, Sandra, Delisle, Jean-Sébastien, Lachance, Silvy, Kiss, Thomas, Roy, Denis-Claude, Sauvageau, Guy, and Roy, Jean

Subjects
*STEM cell transplantation, *MULTIPLE myeloma, *INDUCTION chemotherapy, *OVERALL survival, *PROGRESSION-free survival
Abstract

Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the optimal strategy prior to and doses of DLIs remain unclear. With this study (NCT03413800), we aimed to investigate the efficacy and toxicity of lenalidomide and dexamethasome (Len/Dex) followed by escalating pre-determined doses of DLIs in MM patients who relapsed after allo HCT. Methods: Patients aged 18–65 years with relapsed MM following upfront tandem autologous (auto)/allo HCT were eligible. Treatment consisted of six cycles of Len/Dex followed by three standardized doses of DLIs: 5 × 106 CD3+/kg, 1 × 107/kg and 5 × 107/kg every 6 weeks. Bone marrow minimal measurable disease (MRD) using flow cytometry (10−5) was performed at enrolment, then every 3 months for 2 years or until disease progression, in a subset of patients. The primary endpoint was efficacy as measured by progression-free survival (PFS) at 2 years following Len/Dex/DLIs. Secondary objectives were safety including GVHD, response including MRD status and overall survival (OS). Results: A total of 22 patients participated in this study, including 62% with high-risk cytogenetics. With a median follow-up of 5.3 years (range: 4.1–6.1), PFS and OS were 26.5% (95% CI: 10.4–45.9%) and 69.2% (95% CI: 43.3–85.1%), respectively. Overall, the best responses achieved post-Len/Dex + DLIs were complete remission in 9.1%, very good partial response in 50%, and progressive disease in 40.9%. Among the nine patients tested for MRD, only two achieved a negative status after receiving DLIs. Six patients died, all due to disease progression. No acute GVHD was observed after DLIs. We report a very low incidence of moderate/severe chronic GVHD of 18.2% with no need for systemic immunosuppressants one year after diagnosis. No unexpected adverse events were observed. Interestingly, a positive correlation between response to Len/Dex re-induction and response to DLIs was found (p = 0.0032). Conclusions: Our findings suggest that Len/Dex/DLIs in second line treatment after upfront tandem auto/allo HCT in relapsed MM patients remains feasible and safe. With a potential correlation between induction chemotherapy and DLI responses, more potent induction regimens together with higher doses of DLIs should be considered in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

Author

LeBlanc, Richard, Ahmad, Imran, Terra, Rafik, Boudreault, Jean-Samuel, Ogez, David, Lamore, Kristopher, Delisle, Jean-Sébastien, Bambace, Nadia, Bernard, Léa, Cohen, Sandra, Kiss, Thomas, Lachance, Silvy, Landais, Séverine, Lemieux-Blanchard, Émilie, Sauvageau, Guy, Sebag, Michael, Roy, Denis Claude, and Roy, Jean

Published
2022
Full Text
View/download PDF

18. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Author

Moreau, Philippe, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Spicka, Ivan, Baker, Ross, Kihyun, Kim, Martinez, Gracia, Chang-Ki, Min, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Youngil, Koh, Suzuki, Kenshi, Martin, Tom, Quach, Hang, Lim, Andrew, Crowther, Helen, Sia, Hanlon, Hulin, Cyrille, Mohty, Mohamad, Mikala, Gabor, Nagy, Zsolt, Reinoso Segura, Marta, Rosinol, Laura, Yagci, Munci, Turgut, Mehmet, Garg, Mamta, Parmar, Gurdeep, Augustson, Brad, Castro, Nelson, Crusoe, Edvan, Pika, Tomas, Delimpasi, Sosana, Ishizawa, Kenichi, George, Anup, Konstantinova, Tatiana, De La Rubia, Javier, Sung-Hyun, Kim, Maiolino, Angelo, Reiman, Anthony, LeBlanc, Richard, Ito, Shigeki, Tanaka, Junji, Luchinin, Alexander, Kryuchkova, Irina, Martinez, Joaquin, Shustik, Jesse, Karlin, Lionel, Symeonidis, Anargyros, Egyed, Miklos, Petrini, Mario, Cavo, Michele, Uchiyama, Michihiro, Blacklock, Hilary, Arat, Mutlu, Griffin, James, Hunter, Hannah, Buck, Tonda, Anagnostopoulos, Achilles, Konstantopoulos, Konstantinos, Masszi, Tamas, Bringhen, Sara, Gamberi, Barbara, Kawano, Yawara, Jin Seok, Kim, Ozdogu, Hakan, Ozkalemkas, Fahir, Špička, Ivan, Kim, Kihyun, Min, Chang-Ki, Koh, Youngil, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, and Martin, Thomas

Published
2021
Full Text
View/download PDF

19. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.

Author

Tessier, Camille, LeBlanc, Richard, Roy, Jean, Trudel, Sabrina, Côté, Julie, Lalancette, Marc, Boudreault, Jean‐Samuel, Lemieux‐Blanchard, Émilie, Kaedbey, Rayan, and Pavic, Michel

Subjects
*PLASMA cell leukemia, *PLASMA cell diseases, *MULTIPLE myeloma, *PROGNOSIS, *HEMATOLOGIC malignancies
Abstract

Background: Plasma cell leukemia (PCL) is a rare monoclonal gammopathy, associated with short survival. Because of its very low incidence, only a few cohorts have been reported and thus, information on this disease is scarce. The goal of this study was to better understand the clinical features, prognostic factors, and efficacy of modern treatments in both primary PCL (pPCL) and secondary PCL (sPCL). Methods: We performed a retrospective, multicenter study of patients diagnosed with PCL, defined as circulating plasma cells ≥20% of total leukocytes and/or ≥2 × 109/L. Results: We identified 99 eligible PCL patients, of whom 33 were pPCL and 66 were sPCL. The median progression‐free survival (PFS) to frontline treatment and overall survival (OS) were, respectively, 4.8 (95% CI, 0.4–9.2) and 18.3 months (95% CI, 0.0–39.0) for pPCL and 0.8 (95% CI, 0.5–1.1) and 1.2 months (95% CI, 0.9–1.5) for sPCL (both p < 0.001). We observed no improvement in OS over time (2005–2012 vs. 2013–2020, p = 0.629 for pPCL and p = 0.329 for sPCL). Finally, our data suggested that sPCL originates from a high‐risk multiple myeloma (MM) population with a short OS (median 30.2 months), early relapse after stem cell transplant (median 11.9 months) and a high proportion of patients with multiple cytogenetic abnormalities (36% with ≥2 abnormalities). Conclusions: This study is one of the largest PCL cohorts reported. We are also the first to investigate characteristics of MM before its transformation into sPCL and demonstrate that high‐risk biologic features already present at the time of MM diagnosis. Moreover, our data highlights the lack of improvement in PCL survival in recent years and the urgent need for better treatment options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Ghost cells: Wilder Penfield and the characterization of glia and glial pathology, 1924–1932.

Author

Groh, Adam M.R. and Leblanc, Richard

Subjects
*NEUROGLIA, *CENTRAL nervous system, *PARTIAL epilepsy, *CRANIOCEREBRAL injuries, *MICROGLIA
Abstract

Wilder Penfield is known for his contributions to the structure–function relationship of the brain and for the surgical treatment of focal epilepsy. Less well known are his contributions to the study of glial cells and his investigation of their role in human neuropathology. Penfield learned the gold and silver methods for staining neurons, glial cells, and their projections from Charles Sherrington and Pío del Río-Hortega. He and his colleague William Cone established a laboratory for the study of glial cells and human neuropathology using metallic stains, initially at the Presbyterian Hospital in New York City in 1925, and then at the Montreal Neurological Institute in 1928. Penfield, Cone, and their research fellows, building on the findings of Río-Hortega, confirmed the existence of oligodendrocytes and their relationship with myelin, and investigated the putative mesodermal origin of microglia. They discovered the reaction of oligodendrocytes to pathological stressors, and the phagocytic activity of microglia in human gliomas. In this article, we argue that Penfield’s studies of astrocytes, oligodendrocytes, and microglia, and their responses to craniocerebral trauma, epilepsy, malignant brain tumors, and other pathologies of the central nervous system inaugurated a new era in clinical neurocytology and neuropathology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The Pavlovian interpretation of speech and aphasia: Alexander Luria and Wilder Penfield.

Author

Leblanc, Richard

Subjects
HIGHER nervous activity, CLASSICAL conditioning, CEREBRAL cortex, SPEECH, APHASIA
Abstract

This paper discusses a neglected aspect of the historiography of aphasia, the role that Pavlovian conditioning played in Alexander Luria's and Wilder Penfield's understanding of the acquisition, expression, and loss of spoken and written speech. Luria was born into a bourgeois family in Tzarist Russia and pursued his research on speech and aphasia under the Soviet regime. Luria's work was condemned in the last years of Stalin's rule, but it received international acclaim in the West after Stalin's death. Penfield was conversant with Pavlov's writing having had a working relationship with one of Pavlov's foremost students, Boris Babkin, who came to McGill University and later to the Montreal Neurological Institute after being jailed and exiled from the Soviet Union for lack of revolutionary fervor. Both Luria and Penfield, the latter as early as 1935, saw in Pavlovian conditioning mediated by specific areas of the human cerebral cortex the basic neurophysiological mechanism underlying speech and thought, and in Penfield's' case, memory, perception, self-awareness, and purposeful behavior. It is concluded that Luria and Penfield independently arrived at a general hypothesis, based on Pavlovian conditioning, that united the localization of speech, the syndromes caused by damage to speech-competent regions, and the putative neurophysiological mechanisms that they believed to underlie speech and higher cortical functions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. A Terminological History of the Acadian Tragedy.

Author

LeBlanc, Richard

Subjects
*GENOCIDE, *CRIMES against humanity, *ETHNIC cleansing, *TRAGEDY (Trauma), *EIGHTEENTH century
Abstract

In his book A Great and Noble Scheme (2005), historian John Mack Faragher explains that the 1755–63 Acadian deportation can be termed “ethnic cleansing,” following contemporary United Nations and scholarly usage of the expression. In this paper, instead of addressing the terms of contemporary UN or scholarship, as Faragher does, to see which terms can be used for the Acadian tragedy, I provide a terminological history of the Acadian tragedy. This terminological history studies the terms used for the Acadian tragedy since the eighteenth century until the early twentieth century and shows how they recur in the mid-twentieth century discussions on genocide. First, I investigate Edmund Burke’s treatment of the Acadian tragedy seen as resulting from acts of destroying, rooting out, and extirpating, and the Abbot Raynal using terms for the tragedy such as embarking, transporting, driving away (later deporting), destroying, perishing, depopulating, and, indirectly, crime against humanity. I also focus on the nineteenth-century account of the Acadian tragedy by Catherine Reed Williams, who expanded Raynal with notions of barbarity, banishment, expulsion, extermination, and moral shock, and on others after her who brought terms for Acadians such as annihilation, atrocity, evacuation, and clearing. Second, I highlight Acadian memory in the 1950s genocide debate in Washington (DC) and how the terminological history of the Acadian tragedy appears in a document Raphael Lemkin had on Acadians. I also explain how Lemkin, unknowingly or not, rearticulated in publications and texts and found in his research the terms already used for Acadians as he addressed his genocide concept. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. The collaboration of Francis Forster and Wilder Penfield in the management of a girl with 'reflex epilepsy'.

Author

Lanska, Douglas J. and Leblanc, Richard

Subjects
*EPILEPSY, *REFLEXES, *WORLD War II
Abstract

In the era after World War II, Francis (Frank) Forster (1912–2006) became a preeminent American neurologist and epileptologist, with international prominence in the study of reflex epilepsy. Forster's interest in reflex epilepsy began with a chance observation of the condition, in 1946, in a four-year-old girl. When medical measures failed to control her somatosensory-evoked seizures, Forster recommended surgery, and then facilitated transfer to Canadian neurosurgeon Wilder Penfield (1891–1976) at the Montreal Neurological Institute. Forster traveled to Montreal for the child's surgery. The surgery on February 27, 1948, proved to be curative for the child, and Forster's interactions with Penfield and epileptologist Herbert Jasper (1906–1999) made a lasting impression. This study reviews the medical and surgical history of this case, which strongly influenced Forster's career. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Against vivisection: Charcot and Pitres' discovery of the human motor cortex and the birth of modern neurosurgery and of the surgical treatment of epilepsy.

Author

Leblanc, Richard

Subjects
*MOTOR cortex, *EPILEPSY, *NEUROSURGERY, *ANIMAL mechanics, *SEIZURES (Medicine)
Abstract

This article addresses the discrepancy between Edouard Hitzig's and David Ferrier's findings on the cortical localization of movements in animals and Jean-Martin Charcot's findings in humans. The results of Hitzig's and Ferrier's vivisections were criticized by experimentalists in England and France as discordant, irreproducible, and inconclusive, and they were rejected by clinicians as irrelevant. Charcot addressed the gap between animal and human motor function by correlating motor deficits and focal epileptic seizures in patients to their autopsy findings. By this method he discovered the functional organization of the human motor cortex and produced the first accurate human motor brain map. Ferrier, William Osler, and Hughlings Jackson acknowledged Charcot's findings, and his findings guided the first neurosurgeons in localizing and resecting intracranial mass lesions presenting with focal epileptic seizures. Although his contributions in these fields have been neglected by modern historians, Charcot made significant contributions to the neurobiology of the human motor system, to epileptology, and to the birth of modern neurosurgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

Author

Côté, Julie, LeBlanc, Richard, Reiman, Anthony, Sebag, Michael, Song, Kevin W., Colasurdo, Gabriele, Del Col, Aldo, McMullen, David, Hay, Annette E., Laferriere, Nicole M.B., Robertson McCurdy, Arleigh B., Roy, Jean, Stakiw, Julie L., Trudel, Suzanne M., White, Darrell J., Loveys, Fraser W., Randell, Edward, Rizkalla, Kamilia S., Bergstrom, Debra J., Kotb, Rami, Louzada, Martha L., Sutherland, Heather J., Tavoularis, Sofia, and Venner, Christopher P.

Published
2020
Full Text
View/download PDF

26. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Author

Royal, Virginie, Leung, Nelson, Troyanov, Stéphan, Nasr, Samih H., Écotière, Laure, LeBlanc, Richard, Adam, Benjamin A., Angioi, Andrea, Alexander, Mariam P., Asunis, Anna Maria, Barreca, Antonella, Bianco, Paola, Cohen, Camille, Drosou, Maria E., Fatima, Huma, Fenoglio, Roberta, Gougeon, François, Goujon, Jean-Michel, Herrera, Guillermo A., Knebelmann, Bertrand, Lepori, Nicola, Maletta, Francesca, Manso, Rita, Motwani, Shveta S., Pani, Antonello, Rabant, Marion, Rennke, Helmut G., Rocatello, Dario, Rosenblum, Frida, Sanders, Paul W., Santos, Afonso, Soto, Karina, Sis, Banu, Touchard, Guy, Venner, Christopher P., and Bridoux, Frank

Published
2020
Full Text
View/download PDF

29. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

Author

Schiller, Gary J., Lipe, Brea C., Bahlis, Nizar J., Tuchman, Sascha A., Bensinger, William I., Sutherland, Heather J., Lentzsch, Suzanne, Baljevic, Muhamed, White, Darrell, Kotb, Rami, Chen, Christine I., Rossi, Adriana, Biran, Noa, LeBlanc, Richard, Grosicki, Sebastian, Martelli, Maurizio, Gunsilius, Eberhard, Špička, Ivan, Stevens, Don Ambrose, Facon, Thierry, Mesa, Mercedes Gironella, Zhang, Chris, Van Domelen, Dane R., Bentur, Ohad S., and Gasparetto, Cristina

Published
2023
Full Text
View/download PDF

31. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Author

Attal, Michel, Richardson, Paul G., Rajkumar, Vincent, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Corzo, Kathryn P., Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C., Harrison, Simon, Janowski, Wojt, Kerridge, Ian, Spencer, Andrew, Delforge, Michel, Fostier, Karel, Vlummens, Philip, Wu, Ka Lung, Leblanc, Richard, Pavic, Michel, Sebag, Michael, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Gregersen, Henrik, Benbouker, Lotfi, Caillot, Denis, Escoffre-Barbe, Martine, Facon, Thierry, Frenzel, Laurent, Hulin, Cyrille, Karlin, Lionel, Kolb, Brigitte, Pegourie, Brigitte, Perrot, Aurore, Tiab, Mourad, Vincent, Laure, Niederwieser, Dietger, Anagnostopoulos, Achilles, Delimpasi, Sosana, Kyrtsonis, Marie-Christine, Symeonidis, Anargyros, Illes, Arpad, Mikala, Gabor, Nagy, Zsolt, Bringen, Sara, Corradini, Paolo, Fabio, Ciceri, Lemoli, Roberto, Liberati, Anna, Nozzoli, Chiara, Zambello, Renato, Iida, Shinsuke, Ikeda, Takashi, Iyama, Satoshi, Matsumoto, Morio, Shimazaki, Chihiro, Sunami, Kazutaka, Suzuki, Kenshi, Uchiyama, Michihiro, Koh, Youngil, Kim, Kihyun, Lee, Jae Hoon, Min, Chang-Ki, Blacklock, Hillary, Goodman, Hugh, Neylon, Annette, Simpson, David, Grosicki, Sebastian, Jurczyszyn, Artur, Walter-Croneck, Adam, Warzocha, Krzysztof, Araujo, Luis, Moreira, Claudia, Doronin, Vadim, Mendeleeva, Larisa, Vorobyev, Vladimir, Vranovsky, Andrej, Alegre, Adrian, Gironella, Mercedes, Gonzalez Perez, Marta Sonia, Montes, Carmen, Ocio, Enrique, Rodriguez, Paula, Hardling, Mats, Lauri, Birgitta, Wang, Ming-Chung, Yeh, Su-Peng, Arat, Mutlu, Demirkan, Fatih, Gulbas, Zafer, Besisik, Sevgi Kalayoglu, Karadogan, Ihsan, Tuglular, Tulin, Unal, Ali, Vural, Filiz, Sive, Jonathan, Streetly, Matthew, Yong, Kwee, Tache, Jason, Richardson, Paul G, Rajkumar, S Vincent, Dimopoulos, Meletios A, Prince, H Miles, Corzo, Kathryn P, and Anderson, Kenneth C

Published
2019
Full Text
View/download PDF

33. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

34. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Author

Lim, Andrew, Grigoriadis, George, Walker, Trish, Nicol, Andrew, LeBlanc, Richard, Reece, Donna, Elemary, Mohamed, Boudreault Pedneault, Jean Samuel, Karlin, Lionel, Facon, Thierry, Attal, Michel, Weisel, Katja, Engelhardt, Monika, Mackensen, Andreas, Quinn, John, Avivi, Irit, Cohen, Amos, Magen-Nativ, Hila, Benyamini, Noam, Cavo, Michele, Larocca, Alessandra, Takezako, Naoki, Suzuki, Kenshi, Kosugi, Hiroshi, Matsumoto, Morio, Iida, Shinsuke, Ishikawa, Takayuki, Kondo, Yukio, Sunami, Kazutaka, Ando, Kiyoshi, Teshima, Takanori, Chou, Takaaki, Iwasaki, Hiromi, Miki, Hirokazu, Matsumura, Itaru, Onishi, Yasushi, Izutsu, Koji, Kizaki, Masahiro, George, Anupkumar, Blacklock, Hillary, Simpson, David, Schjesvold, Fredrik, Waage, Anders, Samoilova, Olga, Nikitin, Evgeniy, Chagorova, Tatiana, McDonald, Andrew, Patel, Moosa, Oriol Rocafiguera, Albert, San Miguel Izquierdo, Jesus, Mateos, Maria, Streetly, Matthew, Forsyth, Peter, Jackson, Graham, Jenkins, Stephen, Rifkin, Robert, Yimer, Habte, McCroskey, Robert, Martincic, Danko, Tarantolo, Stefano, Larson, Sarah, Faroun, Yacoub, Vaughn, Jennifer, Baz, Rachid, Saylors, Gene, Neppalli, Amarendra, Raptis, Anastasios, Fung, Henry, Janosky, Maxwell, Stevens, Don, Coleman, Morton, Costa, Dennis, Cross, Scott, Fanning, Suzanne, Berges, Daniel Farray, Harris, Thomas, Zackon, Ira, Atanackovic, Djordje, Lee, Kelvin, Oliff, Ira, Lee, Wes, Bensinger, William, Lutzky, Jose, Baron, Ari, Hayek, Fadi, Kirschner, Eli, Bharany, Neeraj, Overton, Lindsay, Mannem, Siva, Harroff, Allyson, Jain, Sharad, Roque, Tammy, McIntyre, Kristi, Yasencha, Christopher K, Houck, William, Usmani, Saad Zafar, Oriol, Albert, Rifkin, Robert M, Yimer, Habte Aragaw, McCroskey, Robert Donald, Lim, Andrew Boon Ming, Jagannath, Sundar, Lonial, Sagar, Ghori, Razi Uddin, Farooqui, Mohammed Z H, Marinello, Patricia, and San-Miguel, Jesus

Published
2019
Full Text
View/download PDF

35. Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

Author

Kaedbey, Rayan, Reece, Donna, Venner, Christopher P., McCurdy, Arleigh, Su, Jiandong, Chu, Michael, Louzada, Martha, Jimenez‐Zepeda, Victor H, Mian, Hira, Song, Kevin, Sebag, Michael, Stakiw, Julie, White, Darrell, Reiman, Anthony, Aslam, Muhammad, Kotb, Rami, Bergstrom, Debra, Gul, Engin, and LeBlanc, Richard

Published
2024
Full Text
View/download PDF

39. P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database

Author

Varghese, Julia, primary, Venner, Christopher, additional, Louzada, Martha, additional, Reece, Donna, additional, White, Darrell, additional, Su, Jiandong, additional, Chu, Michael, additional, Jimenez-Zepeda, Victor, additional, McCurdy, Arleigh, additional, Song, Kevin, additional, Mian, Hira, additional, Sebag, Michael, additional, Bergstrom, Debra, additional, Stakiw, Julie, additional, Reiman, Anthony, additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and LeBlanc, Richard, additional

Published
2023
Full Text
View/download PDF

40. OA-49 Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

Author

Oriol, Albert, primary, Sandhu, Irwindeep, additional, Raab, Marc, additional, White, Darrell, additional, LeBlanc, Richard, additional, Raje, Noopur, additional, Ocio, Enrique, additional, Perrot, Aurore, additional, Facon, Thierry, additional, Rodriguez, Cesar, additional, Waesch, Ralph, additional, Amatangelo, Michael, additional, Zhou, Zehua, additional, Wang, Yue, additional, Civardi, Tiziana, additional, Koo, Philip, additional, Maciag, Paulo, additional, Zhu, Daniel, additional, Katz, Jessica, additional, and Richardson, Paul, additional

Published
2023
Full Text
View/download PDF

41. Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Author

LeBlanc, Richard, primary, Mian, Hira, additional, Reece, Donna, additional, Su, Jiandong, additional, Masih‐Khan, Esther, additional, Chu, Michael, additional, Jimenez‐Zepeda, Victor, additional, Sebag, Michael, additional, Song, Kevin, additional, Louzada, Martha, additional, Kotb, Rami, additional, Visram, Alissa, additional, White, Darrell, additional, Stakiw, Julie, additional, Reiman, Antony, additional, Aslam, Muhammad, additional, Bergstrom, Debra, additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and Venner, Christopher, additional

Published
2023
Full Text
View/download PDF

44. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Author

Lonial, Sagar, Weiss, Brendan M, Usmani, Saad Z, Singhal, Seema, Chari, Ajai, Bahlis, Nizar J, Belch, Andrew, Krishnan, Amrita, Vescio, Robert A, Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z, Sutherland, Heather J, Bladé, Joan, Scott, Emma C, Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A, LeBlanc, Richard, Sebag, Michael, Callander, Natalie, Jakubowiak, Andrzej, White, Darrell, de la Rubia, Javier, Richardson, Paul G, Lisby, Steen, Feng, Huaibao, Uhlar, Clarissa M, Khan, Imran, Ahmadi, Tahamtan, and Voorhees, Peter M

Published
2016
Full Text
View/download PDF

45. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

Author

Lesokhin, Alexander, primary, LeBlanc, Richard, additional, Dimopoulos, Meletios A., additional, Capra, Marcelo, additional, Carlo‐Stella, Carmelo, additional, Karlin, Lionel, additional, Castilloux, Jean‐Francois, additional, Forsberg, Peter, additional, Parmar, Gurdeep, additional, Tosikyan, Axel, additional, Pour, Ludek, additional, Ribrag, Vincent, additional, Ribolla, Rossella, additional, Abdallah, Al‐Ola, additional, Le Roux, Nadia, additional, Dong, Liyan, additional, van de Velde, Helgi, additional, Mayrargue, Laurent, additional, Lépine, Lucie, additional, Macé, Sandrine, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

46. A Pilot Study of UM171 Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Stem Cell Transplant in High and Very High-Risk Myeloma Patients

Author

Roy, Jean, primary, Cohen, Sandra, additional, Sauvageau, Guy, additional, Terra, Rafik, additional, Ahmad, Imran, additional, Bambace, Nadia M, additional, Bernard, Lea, additional, Delisle, Jean-Sébastien, additional, Kiss, Thomas, additional, Lachance, Dr. Silvy, additional, Roy, Denis-Claude, additional, Veilleux, Olivier, additional, and LeBlanc, Richard, additional

Published
2023
Full Text
View/download PDF

47. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Author

Dimopoulos, Meletios A., primary, Dytfeld, Dominik, additional, Grosicki, Sebastian, additional, Moreau, Philippe, additional, Takezako, Naoki, additional, Hori, Mitsuo, additional, Leleu, Xavier, additional, LeBlanc, Richard, additional, Suzuki, Kenshi, additional, Raab, Marc S., additional, Richardson, Paul G., additional, Popa McKiver, Mihaela, additional, Jou, Ying-Ming, additional, Yao, David, additional, Das, Prianka, additional, and San-Miguel, Jesús, additional

Published
2023
Full Text
View/download PDF

48. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD

Author

Claveau, Jean-Sébastien, primary, LeBlanc, Richard, additional, Ahmad, Imran, additional, Delisle, Jean-Sébastien, additional, Cohen, Sandra, additional, Kiss, Thomas, additional, Bambace, Nadia M., additional, Bernard, Léa, additional, Lachance, Silvy, additional, Roy, Denis Claude, additional, Sauvageau, Guy, additional, Veilleux, Olivier, additional, and Roy, Jean, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results